(VIANEWS) – Tetra Tech (TTEK), STAAR Surgical Company (STAA), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Tetra Tech (TTEK)
33.6% sales growth and 23.16% return on equity
Tetra Tech, Inc. provides consulting and engineering services worldwide. The company operates through Government Services Group (GSG) and Commercial/International Services Group (CIG) segments. The GSG segment offers early data collection and monitoring, data analysis and information technology, science and engineering applied research, engineering design, construction management, and operations and maintenance services; and climate change and energy management consulting, as well as greenhouse gas inventory assessment, certification, reduction, and management services. This segment serves federal, state, and local governments, and development agencies in water resources analysis and water management, environmental monitoring, data analytics, government consulting, waste management, and a range of civil infrastructure master planning and engineering design markets. The CIG segment provides early data collection and monitoring, data analysis and information management, feasibility studies and assessments, science and engineering applied research, engineering design, construction management, and operations and maintenance services. This segment serves natural resources, energy, and utilities markets, as well as civil infrastructure master planning and engineering design markets. Tetra Tech, Inc. was founded in 1966 and is headquartered in Pasadena, California.
Earnings Per Share
As for profitability, Tetra Tech has a trailing twelve months EPS of $5.61.
PE Ratio
Tetra Tech has a trailing twelve months price to earnings ratio of 29.75. Meaning, the purchaser of the share is investing $29.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.16%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Tetra Tech’s EBITDA is 81.59.
Moving Average
Tetra Tech’s value is higher than its 50-day moving average of $162.51 and way above its 200-day moving average of $149.36.
2. STAAR Surgical Company (STAA)
19.9% sales growth and 7.62% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.63.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 74.27. Meaning, the purchaser of the share is investing $74.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.62%.
Yearly Top and Bottom Value
STAAR Surgical Company’s stock is valued at $46.79 at 11:22 EST, way under its 52-week high of $112.27 and above its 52-week low of $45.00.
3. United Therapeutics Corporation (UTHR)
15.3% sales growth and 17.92% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $14.72.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 16.09. Meaning, the purchaser of the share is investing $16.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.92%.
4. Flowserve Corporation (FLS)
11.5% sales growth and 13.64% return on equity
Flowserve Corporation designs, develops, manufactures, distributes, and services industrial flow management equipment in the United States, Europe, the Middle East, Africa, Asia, and internationally. It operates in two segments, Flowserve Pump Division (FPD) and Flow Control Division (FCD). The FPD segment offers custom and pre-configured pumps and pump systems, mechanical seals, auxiliary systems, replacement parts, upgrades, and related aftermarket services, including installation and commissioning services, seal systems spare parts, repairs, advanced diagnostics, re-rate and upgrade solutions, retrofit programs, and machining and asset management solutions, as well as manufactures a gas-lubricated mechanical seal for use in high-speed compressors for gas pipelines. The FCD segment provides engineered and industrial valve and automation solutions, including isolation and control valves, actuation, controls, and related equipment, as well as equipment maintenance services for flow control systems, including advanced diagnostics, repair, installation, commissioning, retrofit programs, and field machining capabilities. This segment's products are used to control, direct, and manage the flow of liquids, gases, and fluids. The company primarily serves oil and gas, chemical and pharmaceuticals, power generation, and water management markets, as well as general industries, including mining and ore processing, pulp and paper, food and beverage, and other smaller applications. The company distributes its products through direct sales, distributors, and sales representatives. Flowserve Corporation was incorporated in 1912 and is headquartered in Irving, Texas.
Earnings Per Share
As for profitability, Flowserve Corporation has a trailing twelve months EPS of $1.76.
PE Ratio
Flowserve Corporation has a trailing twelve months price to earnings ratio of 21.38. Meaning, the purchaser of the share is investing $21.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.64%.
5. MGP Ingredients (MGPI)
8.6% sales growth and 14.45% return on equity
MGP Ingredients, Inc., together with its subsidiaries, produces and supplies distilled spirits, and specialty wheat proteins and starch food ingredients. It operates through two segments, Distillery Products and Ingredient Solutions. The Distillery Products segment provides food grade alcohol for beverage applications that include bourbon and rye whiskeys, as well as grain neutral spirits, including vodka and gin; and food grade industrial alcohol, which is used as an ingredient in foods, personal care products, cleaning solutions, pharmaceuticals, and various other products. This segment also provides fuel grade alcohol for blending with gasoline; distillers feed and related co-products, such as distillers feed and corn oil; and warehouse services, including barrel put away, storage, and retrieval services, as well as blending services. The Ingredient Solutions segment provides specialty wheat starches for food applications under the Fibersym Resistant Starch, FiberRite RW Resistant Starch, Pregel Instant Starch, and Midsol Cook-up Starch names; specialty wheat proteins for food applications under the Arise and Proterra names; gluten free textured pea proteins; commodity wheat starch for food and non-food applications; and commodity wheat proteins. The company sells its products directly or through distributors to manufacturers and processors of finished packaged goods or to bakeries primarily in the United States, Japan, Thailand, Mexico, and Canada. MGP Ingredients, Inc. was founded in 1941 and is headquartered in Atchison, Kansas.
Earnings Per Share
As for profitability, MGP Ingredients has a trailing twelve months EPS of $4.62.
PE Ratio
MGP Ingredients has a trailing twelve months price to earnings ratio of 26.08. Meaning, the purchaser of the share is investing $26.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.45%.
Volume
Today’s last reported volume for MGP Ingredients is 98744 which is 9.36% below its average volume of 108943.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 802.15M for the twelve trailing months.
Sales Growth
MGP Ingredients’s sales growth is 13.2% for the current quarter and 8.6% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 25.5% and 21.8%, respectively.
6. Park-Ohio Holdings Corp. (PKOH)
5.7% sales growth and 4.94% return on equity
Park-Ohio Holdings Corp. provides supply chain management outsourcing services, capital equipment, and manufactured components in the United States, Europe, Asia, Mexico, Canada, and internationally. It operates through three segments: Supply Technologies, Assembly Components, and Engineered Products. The Supply Technologies segment offers Total Supply Management solution, including engineering and design support, part usage and cost analysis, supplier selection, quality assurance, bar coding, product packaging and tracking, just-in-time and point-of-use delivery, electronic billing, and ongoing technical support services, as well as provides spare parts and aftermarket products; and production components, such as valves, fuel hose assemblies, electro-mechanical hardware, labels, fittings, steering components, and other products. It also engineers and manufactures precision cold-formed and cold-extruded fasteners and other products, including locknuts, SPAC nuts, SPAC bolts, and wheel hardware. The Assembly Components segment manufactures aluminum products, direct fuel injection fuel rails and pipes, fuel filler pipes, and flexible multi-layer plastic and rubber assemblies; turbo charging and coolant hoses; and fluid handling systems. It also offers machining services, as well as value-added services, such as design engineering, machining, and part assembly. The Engineered Products segment designs and manufactures engineered products, including induction heating and melting systems, pipe threading systems, and forged and machined products primarily for ferrous and non-ferrous metals, silicon, coatings, forging, foundry, automotive, and construction equipment industries; engineers and installs mechanical forging presses; sells spare parts; provides field services; and offers aerospace and defense structural components, and rail products, such as railcar center plates and draft lugs. Park-Ohio Holdings Corp. was founded in 1907 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, Park-Ohio Holdings Corp. has a trailing twelve months EPS of $1.13.
PE Ratio
Park-Ohio Holdings Corp. has a trailing twelve months price to earnings ratio of 16.12. Meaning, the purchaser of the share is investing $16.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.94%.
